Antibody HDIT101 misses primary goal in genital herpes trial but hints at fewer recurrences
A single infusion of the antibody HDIT101 didn't cut lesion days versus valacyclovir, but patients had fewer recurrences in a phase 2 trial.
Summary
Genital herpes caused by HSV-2 often recurs, and antiviral pills like valacyclovir have only modest effects. In this phase 2 trial, 122 adults with at least four recurrences a year received either a single 2 g infusion of HDIT101, a humanized antibody, or a placebo infusion. At each outbreak over 180 days, the antibody group took placebo pills and the control group took valacyclovir. The antibody did not beat valacyclovir on the primary endpoint: the share of days with lesions was about 14.6% versus 14.9%. Time to first recurrence was numerically longer (47 vs 39 days) but not statistically significant. Recurrences were fewer with HDIT101 (2.7 vs 3.8, p=.01), but this result followed a missed primary endpoint and should be treated as exploratory. Side effects were mild to moderate and similar between groups. The authors, several with commercial ties to the sponsor, call for further study.
Detailed Summary
Recurrent genital herpes from HSV-2 remains a widespread problem. Nucleoside analogues such as valacyclovir have been the standard treatment for decades, but their clinical efficacy is limited. That has driven interest in new approaches, including antibodies that may work through immune mechanisms rather than by blocking viral replication.
MATCH-2 tested HDIT101, a first-in-class humanized monoclonal antibody, in a randomized, double-blinded, parallel-group phase 2 trial across multiple centers. Participants were HSV-2 seropositive and had at least four anogenital recurrences a year. After an observation phase with swabbing, they were randomized 2:1 at the onset of an outbreak to a single 2 g intravenous HDIT101 infusion or a placebo infusion. Over 180 days, the HDIT101 group took placebo pills at each recurrence and the control group took valacyclovir (500 mg twice daily for 3 days). Viral shedding was tracked by daily swabs for 28 days after infusion and again at day 150.
Of 122 patients in the full analysis set, 103 completed the trial per protocol. The primary endpoint, the percentage of days with lesions after treatment, did not differ between arms (14.6% with HDIT101 vs 14.9% with valacyclovir). Time to first recurrence, the key secondary endpoint, was longer with HDIT101 (median 47 vs 39 days) but not significantly so (p=.11). The recurrence rate was lower with HDIT101 (mean 2.7 vs 3.8, p=.01). Adverse events were mild to moderate and similar across arms.
The authors conclude that HDIT101 is well tolerated as an infusion and may help prevent recurrences, which supports further clinical investigation.
The main caveat is that the trial missed its primary endpoint. Under the ordered testing used to control multiplicity, later findings such as the recurrence-rate result are best viewed as hypothesis-generating. Several authors are founders, shareholders or employees of the developer, and this summary is based only on the abstract.
Key Findings
- A single 2 g HDIT101 infusion did not reduce the percentage of days with lesions versus episodic valacyclovir (14.6% vs 14.9%).
- Median time to first recurrence was 47 days with HDIT101 versus 39 with valacyclovir, not statistically significant (p=.11).
- Mean recurrence rate over 180 days was lower with HDIT101 (2.7 vs 3.8, p=.01), but this followed a missed primary endpoint.
- Adverse events were mild to moderate and similar between the antibody and control arms.
- Per-protocol completion was 67 of 81 in the HDIT101 arm and 36 of 41 in the valacyclovir arm.
Methodology
Randomized (2:1), double-blinded, double-dummy, parallel-group phase 2 multicenter trial in HSV-2 seropositive adults with at least four annual recurrences. Patients received a single 2 g IV HDIT101 or placebo infusion at an outbreak, plus episodic valacyclovir or placebo at each recurrence over 180 days. Shedding was assessed by daily anogenital swabs for 28 days and at day 150, with ordered testing to control multiplicity.
Study Limitations
The primary endpoint was not met, so the recurrence-rate finding is exploratory under the ordered testing hierarchy, and time to first recurrence was not significant. Per-protocol analyses and a modest sample size limit robustness, and the sponsor-affiliated authorship and patent interests introduce potential bias. Only the abstract was reviewed, so details on shedding outcomes, exposure, and full safety data are unavailable.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: